banner
EGFR-HER2 inhibitor Zipalertinib, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ040

EGFR-HER2 inhibitor Zipalertinib, Purity ≥98%

Synonym: 1661854-97-2; EGFR-HER2 inhibitor; TAS 6417; TAS-6417

  • CAS Number: 1661854-97-2
  • Compound CID: 117918742
img
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Zipalertinib, soluble in DMSO and ethanol and insoluble in water, is a compound that blocks the activity of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), both of which are involved in driving the growth and proliferation of certain types of cancer cells. It targets EGFR.
Molecular Weight
396.44
Molecular Formula
C23H20N6O
Targets
EGFR: 1.1-8.0 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 71 mg/mL (179.09 mM); Water: Insoluble; Ethanol: 71 mg/mL (179.09 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
EGFR-HER2 inhibitor Zipalertinib is applied in the exploration of inhibiting EGFR and HER2-driven pathways, essential for developing targeted cancer treatments.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0